SEC FORM 3

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Woodworth Emily

(Last)

(First)

(Middle)

300 BOSTON SCIENTIFIC WAY

(Street)

MARLBOROUGH

01752-1234

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
03/01/2024

3. Issuer Name and Ticker or Trading Symbol
BOSTON SCIENTIFIC CORP [ BSX ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	SVP, Global Controller and CAO

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	3,861	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Restricted Stock Units	⁽¹⁾	02/12/2028⁽¹⁾	Common Stock	1,923	⁽²⁾	D
Restricted Stock Units	⁽³⁾	02/14/2027⁽³⁾	Common Stock	1,983⁽⁴⁾	⁽²⁾	D
Restricted Stock Units	⁽⁵⁾	02/16/2026⁽⁵⁾	Common Stock	1,273⁽⁶⁾	⁽²⁾	D
Restricted Stock Units	⁽⁷⁾	02/17/2025⁽⁷⁾	Common Stock	667⁽⁸⁾	⁽²⁾	D
Stock Option (Right to Buy)	⁽⁹⁾	02/17/2031	Common Stock	8,332	$37.5	D
Stock Option (Right to Buy)	⁽¹⁰⁾	02/18/2030	Common Stock	7,218	$42.16	D
Stock Option (Right to Buy)	⁽¹¹⁾	02/16/2032	Common Stock	4,237	$44.19	D
Stock Option (Right to Buy)	⁽¹²⁾	02/14/2033	Common Stock	5,955	$47.28	D
Stock Option (Right to Buy)	⁽¹³⁾	02/12/2034	Common Stock	5,908	$64.99	D

Explanation of Responses:

1. Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 12, 2025, the first anniversary of the date of grant.

2. Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

3. Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant.

4. This amount represents the unvested portion of RSUs awarded on February 14, 2023, which will continue to vest in three remaining installments on the anniversary of the date of grant.

5. Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant.

6. This amount represents the unvested portion of RSUs awarded on February 16, 2022, which will continue to vest in two remaining installments on the anniversary of the date of grant.

7. Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant.

8. This amount represents the unvested portion of RSUs awarded on February 17, 2021, which will continue to vest in one remaining installment on the anniversary of the date of grant.

9. Grant to the reporting person of an option to purchase 9,532 shares of common stock vesting in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant.

10. Grant to the reporting person of an option to purchase 7,218 shares of common stock vesting in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant.

11. Grant to the reporting person of an option to purchase 8,473 shares of common stock vesting in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant.

12. Grant to the reporting person of an option to purchase 7,939 shares of common stock vesting in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant.

13. Grant to the reporting person of an option to purchase 5,908 shares of common stock vesting in four equal annual installments beginning on February 12, 2025, the first anniversary of the date of grant.

Remarks:

collinspoa.txt

	/s/ Susan Thompson, Attorney-in-Fact	03/04/2024
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.